Petros Christopoulos

Jun 12, 2024 | nature.com | Jan Budczies |Eva Romanovsky |Olaf Neumann |Thorsten Stiewe |Daniel Kazdal |Petros Christopoulos

AbstractPredictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information. The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic alterations.

Feb 28, 2024 | cco.amegroups.org | Petros Christopoulos

Published by AME Publishing Company Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China. Email: [email protected]

Nov 1, 2023 | frontiersin.org | Qin Chen |Petros Christopoulos |Janaki Deepak |Giulio Rossi

Highlights1. EML4-ALK+ Neuroendocrine lung cancer treated with ALK-TKI inhibitors showed a rapid response;2. Large cell Neuroendocrine cancer patients with ALK fusion are mostly nonsmoking, young, and female;3. Routine ALK IHC is recommended in advanced large-cell neuroendocrine cancer patients.